Search

Arcutis Biotherapeutics Inc

Отворен

СекторЗдравеопазване

28.27 0.53

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

27.7

Максимум

28.86

Ключови измерители

By Trading Economics

Приходи

-6.2M

8.8M

Продажби

14M

144M

P/E

Средно за сектора

119.091

68.089

EPS

0.06

Марж на печалбата

6.115

Служители

354

EBITDA

-4.6M

13M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+53.37% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-616M

3.3B

Предишно отваряне

27.74

Предишно затваряне

28.27

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.11.2026 г., 21:01 ч. UTC

Arcutis Biotherapeutics, Inc. is advancing today.

10.11.2026 г., 21:06 ч. UTC

Arcutis Biotherapeutics, Inc. shares are higher today, showing a strong early surge.

6.11.2026 г., 21:02 ч. UTC

News
Event
Macro Event

Arcutis Biotherapeutics grants 58.5k restricted stock units and options for 17k shares to new employees, while enrolling the first participant in a Phase 3 study.

5.11.2026 г., 23:26 ч. UTC

Event

Arcutis Biotherapeutics enrolls the first participant in its Phase 3 study, INTEGUMENT-3, amid significant declines in after-market trading.

4.11.2026 г., 23:02 ч. UTC

News

Arcutis Biotherapeutics reports Q3 net income of $8.8M and revenue of $143.9M, but EPS of $0.06 misses expectations, leading to negative market sentiment.

3.11.2026 г., 23:21 ч. UTC

Arcutis Biotherapeutics, Inc. shares are trading modestly lower in after-market hours, following a strong one-month performance above its 20-day moving average.

2.11.2026 г., 21:09 ч. UTC

Correlated Moves

Arcutis Biotherapeutics shares are declining amid broader weakness in the biotechnology sector, influenced by significant drops in key holdings within the SPDR S&P Biotech ETF.

30.10.2026 г., 19:36 ч. UTC

Arcutis Biotherapeutics, Inc. is seeing modest gains, recovering from an earlier pullback and trading above its 20-day moving average.

29.10.2026 г., 21:21 ч. UTC

Arcutis Biotherapeutics, Inc. is trading modestly higher in after-market hours, reflecting strength in the Biotechnology sub-sector and continuing a strong performance trend.

27.10.2026 г., 19:26 ч. UTC

Arcutis Biotherapeutics, Inc. shares fell slightly, retracing some gains but remaining above its 20-day moving average and near the upper end of its one-month range.

26.10.2026 г., 20:13 ч. UTC

Arcutis Biotherapeutics Inc shares are trading lower in after-market hours, continuing a downward trend that began since Monday's close.

23.10.2026 г., 20:01 ч. UTC

Arcutis Biotherapeutics Inc shares are declining sharply, with a cumulative return significantly lower since Thursday's close, reflecting weaker performance compared to recent trends.

22.10.2026 г., 20:07 ч. UTC

Social Media

Arcutis Biotherapeutics Inc shares are modestly higher, approaching their 52-week high, amid strong sales of ZORYVE and anticipation for Q3 earnings.

21.10.2026 г., 19:36 ч. UTC

Arcutis Biotherapeutics Inc shares fell sharply, retracing from earlier gains.

20.10.2026 г., 22:26 ч. UTC

Arcutis Biotherapeutics Inc shares are trading modestly lower in after-market hours, having retraced from a brief peak earlier in the session.

19.10.2026 г., 22:01 ч. UTC

Arcutis Biotherapeutics Inc is trading higher in after-market hours, following a strong position after Monday's close, despite a decline in the NAHB Housing Market Index.

16.10.2026 г., 20:13 ч. UTC

Arcutis Biotherapeutics Inc shares declined during after-market hours, aligning with broader market trends amid mixed economic data on inflation and fiscal management.

15.10.2026 г., 20:01 ч. UTC

News

Cantor Fitzgerald initiated coverage on Arcutis Biotherapeutics with an Overweight rating and a price target of $48, contributing to notable trading volume.

14.10.2026 г., 22:52 ч. UTC

Arcutis Biotherapeutics Inc shares are moving modestly lower in after-market hours, reflecting a broader market decline following a consumer inflation report.

13.10.2026 г., 20:07 ч. UTC

Arcutis Biotherapeutics Inc shares fell modestly, reaching a low in the morning before recovering but ultimately settling near the lower end of its range.

12.10.2026 г., 20:06 ч. UTC

Event

Arcutis Biotherapeutics presented data on its ZORYVE® portfolio at two dermatology conferences, leading to a decline in shares during Monday's session.

9.10.2026 г., 20:01 ч. UTC

Event
Macro Event
News

Arcutis Biotherapeutics presents positive ZORYVE data at EADV Congress, showing 34.4% of infants and 66.4% of patients achieving clear skin in trials.

8.10.2026 г., 20:03 ч. UTC

Arcutis Biotherapeutics Inc shares are gaining.

6.10.2026 г., 20:00 ч. UTC

Event

Shares of Arcutis Biotherapeutics Inc fell despite the company's ZORYVE® cream winning the 2026 "Best Prescription Skin Solution" Award from Marie Claire magazine.

1.10.2026 г., 20:07 ч. UTC

Arcutis Biotherapeutics Inc shares fell sharply, continuing a trend of three consecutive lower daily closes amid challenges in the biotechnology sector.

29.09.2026 г., 20:07 ч. UTC

News

Arcutis Biotherapeutics launched the "Skin to Believe In" campaign with Simone Biles, as shares fell lower after an initial gain at market open.

28.09.2026 г., 19:15 ч. UTC

Arcutis Biotherapeutics Inc is trading higher, reaching a peak return of nearly 2% and remaining significantly above its 20-day moving average.

25.09.2026 г., 20:07 ч. UTC

Arcutis Biotherapeutics Inc is advancing during the session, building on gains since Thursday, trading above its 20-day moving average and near its one-month high.

24.09.2026 г., 20:07 ч. UTC

Arcutis Biotherapeutics Inc's shares fell, continuing a downward trend since Wednesday, despite earlier fluctuations that saw a pullback from a session high.

23.09.2026 г., 20:01 ч. UTC

Arcutis Biotherapeutics Inc shares fell sharply, breaking a recent trend of higher daily closes, diverging from the upward movement observed in prior sessions.

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

53.37% нагоре

12-месечна прогноза

Среден 42 USD  53.37%

Висок 48 USD

Нисък 38 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

5

Купи

0

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
help-icon Live chat